Revolution Medicines reported a landmark survival benefit for its investigational RAS-targeting drug daraxonrasib (RMC-6236) in a global Phase 3 trial in metastatic pancreatic ductal adenocarcinoma. In RASolute 302, the company said median overall survival was 13.2 months with daraxonrasib versus 6.7 months with standard chemotherapy. The trial, which included a broad mix of RAS genotypes, also showed improvements in progression-free survival and a manageable safety profile with no new safety signals reported in the release. Revolution said it plans to use the data to pursue FDA approval, though timing was not specified. The significance for biotech is high: pancreatic cancer has historically resisted targeted approaches, and a positive readout for a RAS-state inhibitor could quickly reframe the competitive landscape for developers targeting MAPK and related pathways.